scholarly journals PGE2 Modulates GABAA Receptors via an EP1 Receptor-Mediated Signaling Pathway

2015 ◽  
Vol 36 (5) ◽  
pp. 1699-1711 ◽  
Author(s):  
Guang Yang ◽  
Wen-Hao Dong ◽  
Chang-Long Hu ◽  
Yan-Ai Mei

Aims: PGE2 is one of the most abundant prostanoids in mammalian tissues, but its effect on neuronal receptors has not been well investigated. This study examines the effect of PGE2 on GABAA receptor currents in rat cerebellar granule neurons. Methods: GABAA currents were recorded using a patch-clamp technique. Cell surface and total protein of GABAA β1/2/3 subunits was carried out by Western blot analysis. Results: Upon incubation of neurons with PGE2 (1 µM) for 60 minutes, GABAA currents were significantly potentiated. This PGE2-driven effect could be blocked by PKC or CaMKII inhibitors as well as EP1 receptor antagonist, and mimicked by PMA or EP1 receptor agonist. Furthermore, Western blot data showed that PGE2 did not increase the total expression level of GABAA receptors, but significantly increased surface levels of GABAA β1/2/3 subunits after 1 h of treatment. Consistently, both PKC and CaMKII inhibitors were able to reduce PGE2-induced increases in cell surface expression of GABAA receptors. Conclusion: Activation of either the PKC or CaMKII pathways by EP1 receptors mediates the PGE2-induced increase in GABAA currents. This suggests that upregulation of postsynaptic GABAA receptors by PGE2 may have profound effects on cerebellar functioning under physiological and pathological conditions.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3088-3088 ◽  
Author(s):  
Kim E. Olson ◽  
Dianne Pulte ◽  
Marinus Johan Broekman ◽  
Ashley E. Olson ◽  
Joan Drosopoulos ◽  
...  

Abstract Blood-borne cellular elements expressing ectonucleotidase activity have been shown to regulate platelet activation and recruitment in response to agonists. In particular, exposure of a platelet releasate to isolated neutrophils (PMN) results in loss of its platelet activating activity in a subsequent assay (Valles et al, J Clin Invest1993, 92:1357–1365). Whereas expression of CD39 on vascular endothelial cells has been well characterized, expression on leukocytes has been less well studied. Freshly prepared lymphocyte and PMN cell populations were evaluated for both cell surface expression of CD39 and ectonucleotidase activity. FACS analysis showed that 98% of PMN were positive for CD39 compared to only 20% of lymphocytes. In addition, neutrophils stained more intensely, indicating the presence of a higher quantity of cell surface-expressed CD39. Interestingly, neutrophils exhibited only 1/3 of the ATPase and 1/2 of the ADPase activities of the same number of lymphocytes, although the latter are thought to have greater antithrombotic capacity. RT-PCR products from total RNA isolated from lymphocytes and PMN were sequenced. This revealed alternately spliced CD39 mRNA species present in PMN at levels equal to that of CD39 mRNA. In contrast, lymphocytes, which showed much higher levels of CD39 mRNA, expressed these variants at much lower levels. RACE analyses of cDNAs generated from total RNA demonstrated two CD39 gene-derived mRNAs. Each was comprised of an alternate 3′ segment lacking the C-terminal transmembrane domain, and distinguished by an internal deletion. Myc- and Flag-tagged constructs expressed in COS cells resulted in cell surface expression of the respectively tagged variants (immunocytochemistry, western blot analyses of plasma membrane preparations). Membrane preparations assayed for enzyme activity revealed no apyrase activity for either molecule expressed alone or together. Co-transfection of CD39 with equal amounts of either construct singly or in combination resulted in a 30-50% decrease in ATPase activity compared to CD39 alone. Similarly, CD39 co-expressed with either construct alone lost 75–90% of its ADPase activity. Unexpectedly, co-transfection of CD39 with both variants together resulted in a 20–40% increase in ADPase activity. Glutaraldehyde cross-linking of membrane preparations from triply transfected COS cells followed by immunoprecipitation and western blot analyses demonstrated the presence of all three species in higher order complexes. Thus, both variants can simultaneously associate with CD39, generating hetero-multimers with altered substrate preference and catalytic efficiency compared to CD39 tetramers. These observations add to our understanding of the regulation of ectonucleotidase activity at the cell surface. The balanced expression of CD39 and its two identified variants may underlie the anti-platelet activity of neutrophils previously reported. The finding that association of CD39 with either construct alone results in near complete loss of ADPase activity with only partial diminution of ATPase activity suggests a possible etiology for a pro-thrombotic phenotype.


2010 ◽  
Vol 1346 ◽  
pp. 1-13 ◽  
Author(s):  
Randa S. Eshaq ◽  
Letha D. Stahl ◽  
Randolph Stone ◽  
Sheryl S. Smith ◽  
Lucy C. Robinson ◽  
...  

2002 ◽  
Vol 368 (2) ◽  
pp. 495-505 ◽  
Author(s):  
Steven J. COMPTON ◽  
Sabrina SANDHU ◽  
Suranga J. WIJESURIYA ◽  
Morley D. HOLLENBERG

We have analysed the role of N-linked glycosylation in regulating human proteinase-activated receptor-2 (hPAR2) expression and function. Epitope-tagged wild-type hPAR2 (wt-hPAR2) or hPAR2 that lacked glycosylation sequons (following site-directed mutagenesis) in either the N-terminus [hPAR2N30A (Asn30→Ala)], extracellular loop 2 [ECL2; hPAR2N222Q (Asn222→Gln) or hPAR2N222A (Asn222→Ala)] or both (hPAR2N30A,N222A or hPAR2N30A,N222Q) were expressed in the Chinese-hamster ovary (CHO) fibroblast cell line, Pro5. Western blot analysis of wt-hPAR2 showed mature wt-hPAR2 to have a molecular mass of 55—100kDa, and 33—48kDa following N-glycosidase F deglycosylation. FACS analysis and immunocytochemistry of the wt-hPAR2 and PAR2 mutant cell lines revealed that removal of both glycosylation sequons decreases (50% of wt-hPAR2) cell surface expression. Western blot analysis indicated that both N-linked sites are glycosylated. In functional studies, hPAR2N30A displayed a selective and significant increase in sensitivity towards tryptase. Interestingly, hPAR2N222A displayed a loss in sensitivity towards all PAR2 agonists tested. However, further analysis revealed receptor sensitivity to alanine mutations in this domain, as the more conservative substitution hPAR2N222Q displayed no change in response to PAR2 agonists. hPAR2N30A,N222Q displayed increased sensitivity towards tryptase, but a loss in sensitivity towards trypsin and the synthetic peptide SLIGRL-NH2, although this loss in sensitivity towards trypsin and SLIGRL-NH2 was secondary to changes in cell-surface expression. Finally, expression of sialic-acid-deficient wt-hPAR2 in the CHO Lec2 glycosylation-deficient mutant cell line, showed a 40kDa loss in molecular mass, in addition to a marked and selective increase in sensitivity towards tryptase. We conclude that hPAR2 N-linked glycosylation and sialylation regulates receptor expression and/or signalling.


2020 ◽  
Author(s):  
Florent Colomb ◽  
Leila B. Giron ◽  
Leticia Kuri Cervantes ◽  
Tongcui Ma ◽  
Samson Adeniji ◽  
...  

Author(s):  
Mona Aslani ◽  
Arman Ahmadzadeh ◽  
Zahra Aghazadeh ◽  
Majid Zaki-Dizaji ◽  
Laleh Sharifi ◽  
...  

Background: : Based on the encouraging results of phase III clinical trial of β-D-mannuronic acid (M2000) (as a new anti-inflammatory drug) in patients with RA, in this study, we aimed to evaluate the effects of this drug on the expression of chemokines and their receptors in PBMCs of RA patients. Methods:: PBMCs of RA patients and healthy controls were separated and the patients' cells were treated with low, moderate and high doses (5, 25 and 50 μg/mL) of M2000 and optimum dose (1 μg/mL) of diclofenac, as a control in RPMI-1640 medium. Real-time PCR was used for evaluating the mRNA expression of CXCR3, CXCR4, CCR2, CCR5 and CCL2/MCP-1. Cell surface expression of CCR2 was investigated using flow cytometry. Results:: CCR5 mRNA expression reduced significantly, after treatment of the patients' cells with all three doses of M2000 and optimum dose of diclofenac. CXCR3 mRNA expression down-regulated significantly followed by treatment of these cells with moderate and high doses of M2000 and optimum dose of diclofenac. CXCR4 mRNA expression declined significantly after treatment of these cells with moderate and high doses of M2000. CCL2 mRNA expression significantly reduced only followed by treatment of these cells with high dose of M2000, whereas, mRNA and cell surface expressions of CCR2 diminished significantly followed by treatment of these cells with high dose of M2000 and optimum dose of diclofenac. Conclusion:: According to our results, M2000 through the down-regulation of chemokines and their receptors may restrict the infiltration of immune cells into the synovium.


1990 ◽  
Vol 64 (10) ◽  
pp. 4776-4783 ◽  
Author(s):  
M E Andrew ◽  
D B Boyle ◽  
P L Whitfeld ◽  
L J Lockett ◽  
I D Anthony ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document